The offices of cosmetic bill sponsors in the last Congress say the Personal Care Products Safety Act and the considerably more industry-friendly Cosmetics Modernization Amendments proposal will both be reintroduced this year. The latter’s relaunch may be imminent, and the stage could be set for it – or at least some of its pro-business provisions – to earn a more serious look in the new Congress.
The 114th Congress ended with cosmetics legislation stalled in committee despite bipartisan support, broad-based stakeholder backing and other auspicious factors that made 2016 feel like a rare opportunity.
President Obama had already signed into law the Microbead-Free Waters Act, banning the heaviest plastic microbeads use in cosmetics, the...
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
P&G's FY2024 Q4 net sales were flat at $20.5bn, lower than consensus estimates, but the firm says its underlying business divisions are healthy and forecasts FY2025 sales up 2% to 4%, up 3% to 5% organically.
Legislator education is key to checking state bills that overreach, says Ross, executive VP of government affairs at the Personal Care Products Council, discussing the rising tide of US state bills aimed at restricting ingredient use.
FDA reminds companies which registered with agency solely to manufacture OTC sanitizers during COVID-19 public health emergency they will be subject to FY2025 OTC monograph user fees if they don’t delist and deregister as monograph drug manufacturers by 12 a.m. on 31 December.
With monographs@FDA portal down, agency moves to NextGen and extends comment period through 27 September for first OTC monograph change it proposed using its overhauled program other than 32 monographs finalizations required in 2020 legislation authorizing overhaul.
OTC sales edged up at Italy's Recordati in the first half of 2024 as higher demand for GI products and supplements offset a weaker cold & flu season.
P&G's FY2024 Q4 net sales were flat at $20.5bn, lower than consensus estimates, but the firm says its underlying business divisions are healthy and forecasts FY2025 sales up 2% to 4%, up 3% to 5% organically.
